Physician profile
Daniel A Frederick
NPI 1801973581
$8,522.09
in general payments reported to CMS, 2019-2025
25 companies · $887 in 2025
The $887 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,064 · 2020: $308 · 2021: $1,322 · 2022: $1,975 · 2023: $1,916 · 2024: $1,050 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,852.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,632.29 | 2019-2025 | Proclaim, Octrode |
| Spinal Simplicity, LLC | $1,016.92 | 2022-2023 | Ha Minuteman G3-R |
| Boston Scientific Corporation | $788.22 | 2019-2023 | |
| Medtronic, INC. | $658.43 | 2022-2025 | Primeadvanced Surescan, Intellis Adaptivestim |
| Nevro Corp. | $527.05 | 2019-2023 | Senza |
| Foundation Fusion Solutions, LLC | $506.84 | 2021 | |
| Spr Therapeutics, INC | $494.11 | 2023 | Sprint Pns System |
| Biotronik Nro, INC. | $426.37 | 2024 | Prospera |
| Nalu Medical, INC. | $301.52 | 2020-2025 | Nalu Neurostimulation System |
| Medtronic USA, INC. | $222.66 | 2020 | |
| Zynex Medical, INC. | $134.87 | 2025 | Nexwave |
| Vertiflex, INC. | $129.51 | 2019 | |
| Biodelivery Sciences International, INC. | $128.39 | 2019 | |
| Abbvie INC. | $127.82 | 2021-2025 | |
| Relievant Medsystems, INC. | $97.45 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $76.70 | 2023-2025 | |
| Bioventus LLC | $60.14 | 2022 | |
| Averitas Pharma INC. | $42.28 | 2023-2024 | Qutenza |
| Teva Pharmaceuticals USA, INC. | $40.33 | 2019-2020 | |
| Allergan, INC. | $29.95 | 2022 | |
| Collegium Pharmaceutical, INC. | $21.07 | 2025 | Belbuca |
| Grt US Holding, INC. | $16.28 | 2022 | |
| Painteq LLC | $16.00 | 2023 | Painteq |
| Pacira Therapeutics, INC. | $15.44 | 2021 | |
| Amgen INC. | $11.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Frederick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.